Antisense therapy for lymphomas

Hematological Oncology

Volumn 15, Issue 1, 1997, Pages 3-11

  Cotter, Finbarr E ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; COMPLEMENTARY DNA; MESSENGER RNA; PHOSPHOROTHIOIC ACID DERIVATIVE; PROTEIN BCL 2; SINGLE STRANDED DNA;

CHROMOSOME TRANSLOCATION; DRUG DESIGN; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE TARGETING; GENE THERAPY; HUMAN; HYPERGLYCEMIA; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA; NONHUMAN; NUCLEIC ACID PROBE; ONCOGENE MYC; PRIORITY JOURNAL; REVIEW; RNA TRANSLATION; SILENCER GENE; THROMBOCYTOPENIA;

ANIMALS; DNA, SINGLE-STRANDED; HUMANS; LYMPHOMA; OLIGONUCLEOTIDES, ANTISENSE; THIONUCLEOTIDES;

EID: 0030985448     PISSN: 02780232     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1069(199702)15:1<3::AID-HON583>3.0.CO;2-S     Document Type: Review

References (44)

1. Zamecnik, P., Stephensen, M. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide, Proc. Natl. Acad. Sci. U.S.A. 1978, 75, 280-284.
2. Daaka, Y., Wickstrom, E. Target dependence of antisense oligodeoxynucleotide inhibition of c-H-ras p21 expression and focus formation in T24-transformed NIH3T3 cells. Oncogene Res. 1990, 5, 267-275.
3. Bacon, T., Wickstrom, E. Walking along human c-myc mRNA with antisense oligodeoxynucleotides: maximum efficacy at the 5′ cap region. Oncogene Res. 1991, 6, 13-19.
4. Goodchild, J. Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 5507-5511.
5. Szczylik, C., Skorski, T., Nicolaides, N., et al. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science 1991, 253, 562-565.
6. Lima, W. F., Monia, B. P., Ecker, D. J., Freier, S. M. Implication of RNA structure on antisense oligonucleotide, hybridization kinetics. Biochemistry 1992, 31, 12055-12061.
7. Helene, C., Toulme, J. J. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim. Biophys. Acta 1990, 1046, 99-125.
8. Monia, B. P., et al. Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J. Biol. Chem. 1992, 267, 19954-19962.
9. Loke, S., Stein, C., Zhang, X., et al. Characterization of oligonucleotide transport into living cells. Proc. Natl. Acad Sci. U.S.A. 1989, 86, 3474-3478.
10. Yakubov, L., Deeva, E., Zarytova, V., et al. Mechanism of oligonucleotide uptake by cells: Involvement of specific receptors? Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 6454-6458.
11. Kreig, A., Gmelig-Meyling, F., Gourley, M., Kisch, W., Chrisey, L., Steinberg, A. Uptake of oliaodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible. Antisense Res. Dev. 1991, 1, 161-171.
12. Clark. R. E. Poor cellular uptake of antisense oligodeoxynucleotides: an obstacle to their use in chronic myeloid leukaemia. Leuk. Lymphoma 1995, 19, 189-195.
13. Bennett, C. F., Chiang, M. Y., Chan, H., Shoemaker, J. E., Mirabelli, C. K. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 1992, 41, 1023-1033.
14. Eder, P., DeVine, R., Dagle, J., Walder, J. Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3′ exonuclease in plasma. Antisense Res. Dev. 1991, 1, 141-151.
15. Miller, P. Non-ionic oligonucleotides. In: Cohen, J., ed. Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression. London: Macmillan, 1989: 79-95.
16. Stein, C., Cohen, J. Phosphorothioate oligodeoxynucleotide analogues. In: Cohen, J., ed. Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression. London: Macmillan, 1989: 97-117.
17. Nielsen, P. E., Egholm, M., Berg, R. H., Buchardt, O. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 1991, 254, 1497-1500.
18. Wittung, P., Kajanus, J., Edward, K., et al. Phospholipid membrane permeability of peptide nucleic acid. 1995, 375, 27-29.
19. Wintersberger, U. Ribonucleases H of retroviral and cellular origin. Pharmcol. Ther. 1990, 48, 259-280.
20. Dash, P., Lotan, I., Knapp, M., Kundel, E., Goelet, P. Selective elimination of mRNAs in vivo: complementary oligodeoxynucleotides promote RNA degradation by an RAase H-like activity. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 7896-7900.
21. Walder, R., Walder, J. Role of RNase-H in hybrid-arrested translation by antisense olieonucleotides. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 5011-5015.
22. Boiziau, C., Kurfurst, R., Cazenave, C., Roig, V., Thuong, N., Toulme, J.-J. Inhibition of translation initiation by antisense oligonucleotides via an RNase-H independent mechanism. Nucl. Acid. Res. 1991, 19, 1113-1119.
23. Wellstein, A., Zugmaier, G., Califano, J., Kern, F., Paik, S., Lippman, M. Tumor growth dependent of Kaposi's sarcoma derived fibroblast growth factor inhibited by pentosan polysulfate. J. Natl. Cancer Inst. 1991,83, 716-720.
24. Zugmaier, G., Lippman, M., Wellstein, A. Inhibition by pentosan polysulfate (PPS) of heparinbinding growth factors released from tumor cells and blockage by PPS of tumor growth in animals. J. Natl. Cancer Inst. 1993, 84, 1716-1724.
25. Stein, C., Cleary, A., Yakubov, L., Lederman, S. Phosphorothioate oligodeoxynucleotides bind to the third variable loop domain (v3) of HIV-1 gp120. Antisense Res. Dev. 1993, 3, 19-31.
26. Yamamoto, S., Yamamoto, T., Kataoka, T., Kuramoto, E., Yano, O., Tokunaga, T. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity. J Immunol. 1992, 148, 4072-4076.
27. Milligan, J., Matteucci, M., Martin, J. Current concepts in antisense drug design. J. Med. Chem. 1993, 36, 1923-1937.
28. Cotter, F., Johnson, P., Hall, P., et al. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 1994, 9, 3049-3055.
29. Pocock, C., Malone, M., Booth, M., et al. BCL-2 expression by leukaemic blasts in a SCID mouse model of biphenotypic leukaemia model associated with the t(4;11)(q21;q23) translocation. Br. J. Haemal. 1995,
30. Ratajczak, M., Kant, J., Luger, S., el al. In vivo treatment of human leukemia in a SCID mouse model with c-myb antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 11823-11827.
31. Skorski, T., Neiborowska-Skorska, M., Nicolaides, N., et al. Suppression of Philadelphia leukemic cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc. Natl. Acad. Sci U.S.A. 1994, 91, 4504-4508.
32. Agrawal, S., Temsamani, J., Tang, J. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci U.S.A. 1991, 88, 7595-7599.
33. Iversen, P. In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue. Anti-Cancer Drug Design 1991, 6, 531-538.
34. Cotter, F. E., Corbo, M., Raynaud, F., et al. Bcl-2 antisense therapy in lymphoma: in vitro and in vivo mechanisms, efficacy, pharmacokinetics and toxicity studies. Ann. Oncol. 1996, 7(Suppl. 3), 32.
35. Bishop, M. R., Iversen, P. L., Bayever, E., et al. Phase I trial of an antisense oligonucleotide OL(1) p53 in haematologic malignancies. J. Clin. Oncol. 1996, 14, 1320-1326.
36. Calabretta, B., Skorski, T., Ratajczak, M. Z., Gewirtz, A. M. Antisense strategies in the treatment of leukemias. Semin. Oncol. 1996, 23, 78-87.
37. Reed, J., Cuddy, M., Haldar, S., et al. BCL2-mediated tumorigenicity of a human T-lymphoid cell line: synergy with MYC and inhibition by BCL2 antisense. Proc. Natl. Acad. Sci U.S.A. 1990, 87, 3660-3664.
38. Reed, J., Stein, C., Subasinghe, C., et al. Antisense-mediated inhibition of BL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res. 1990, 50, 6565-6570.
39. Webb, A., Cunningham, D., Cotter, F., et al. Phase I Bcl-2 antisense trial: preliminary results. Ann. Oncol. 1996, 7(Suppl. 3), 32.
40. Pocock, C., Al-Mahdi, N., Hall, P., Morgan, G., Cotter, F. In vivo suppression of B-cell lymphoma with BCL-2 antisense oligonucleotides (Abstract). Blood 1993, 82(Suppl. 1), 200a.
41. Holt, J., Redner, R., Nienhuis, A. An oligomer complimentary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation. Mol. Cell Biol. 1988, 8, 967-973.
42. Wickstrom, E. L., Bacon, T., Gonzalez, A., Freeman, D., Lyman, G., Wickstrom, E. Human promyelocytic leukemia HL-60 cell prolifration and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 1028-1032.
43. McManaway, M., Neckers, L., Loke, S., et al. Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide. Lancet 1990, 335, 808-811.
44. Monia, B. P., Johnston, J. F., Geiger, T., Muller, M., Fabbro, D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-ra/kinase. Nature Med. 1996, 2, 668-675.